CredoScientia - Bibliothèque

Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report.

BACKGROUND: The effectiveness of combination therapies with multiple mechanisms of action in treating advanced hepatocellular carcinoma (HCC) has been highlighted by the observed synergistic antitumor…

Thérapies de Conversion

Liu, J., Zhao, Z., Tian, Y., & Shao, H. (2025). Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report.. Discov Oncol, 17(1), 33. https://doi.org/10.1007/s12672-025-04132-4

02/12/2025 Lire →

Survival impact of conversion therapy for Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma-a propensity score matching analysis.

Thérapies de Conversion

Ho, K. K. Y., Chiang, C. L., Wong, T., Dai, W. C., Tsang, S., Sin, S. L., Au, K. P., Chan, M. Y., Cheung, T. T., & Chan, A. C. Y. (2025). Survival impact of conversion therapy for Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma-a propensity score matching analysis.. Hepatobiliary Surg Nutr, 14(6), 1063-1077. https://doi.org/10.21037/hbsn-2025-68

01/12/2025 Lire →

Letter to editor "A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocellular carcinoma patients: a tumor marker prognostic stud

Thérapies de Conversion

Wang, B., Shen, N., & Xiao, H. (2025). Letter to editor "A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocellular carcinoma patients: a tumor marker prognostic stud. Int J Surg, 111(12), 9934-9935. https://doi.org/10.1097/JS9.0000000000003203

01/12/2025 Lire →

Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative analysis in a real-world cohort.

BACKGROUND: Conversion therapy offers new hope for patients with unresectable hepatocellular carcinoma (uHCC), thereby becoming a pivotal advancement in the field of liver cancer treatment.METHODS: Th…

Thérapies de Conversion

Ou, Y., Chen, Y., Chen, K., Yao, M., Ling, G., Liao, C., Liu, Y., Cao, H., Li, J., Wang, C., Nong, Y., Chen, J., Huang, F., Huang, Y., Cai, X., & Yan, Y. (2025). Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative analysis in a real-world cohort.. Am J Surg, 250, 116602. https://doi.org/10.1016/j.amjsurg.2025.116602

01/12/2025 Lire →

Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study.

INTRODUCTION: Uncertainty exists regarding whether hepatectomy enhances the prognosis for initially unresectable hepatocellular carcinoma (HCC) that becomes resectable subsequent to conversion therapy…

Thérapies de Conversion

Yang, D. L., Peng, N., Nong, J. L., Chen, K., Su, Z., Yu, Y. Q., Ye, L., Zeng, F. J., Liu, S. P., Yan, Y. H., Wang, X. Y., Yao, H. B., Yang, F. Q., Li, W. F., Qin, C., Wu, M. S., Yang, Y. Y., Dong, X. F., Li, M. J., … GUIDANCE, I. n. v. e. s. t. i. g. a. t. o. r. s. (2025). Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study.. Liver Cancer, 14(6), 687-703. https://doi.org/10.1159/000546052

01/12/2025 Lire →

Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy.

Hepatocellular carcinoma (HCC) remains a health concern characterized by heterogeneity and high mortality. Surgical resection, radiofrequency ablation, trans-arterial chemoembolization, and liver tran…

Thérapies de Conversion

Akabane, M., Imaoka, Y., Kawashima, J., & Pawlik, T. M. (2025). Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy.. Hepat Oncol, 12(1), 2493457. https://doi.org/10.1080/20450923.2025.2493457

01/12/2025 Lire →

Analysis of different prognoses in two hepatocellular carcinoma patients with pathological complete response after conversion therapy: a case report.

BACKGROUND: Hepatocellular carcinoma is a common lethal malignancy, with most patients diagnosed at an advanced stage, precluding surgical resection. Conversion therapy combining locoregional and syst…

Thérapies de Conversion

Fang, Q., Xiong, Y., Zhang, Y., Wang, F., Yin, Z., & Zhou, J. (2025). Analysis of different prognoses in two hepatocellular carcinoma patients with pathological complete response after conversion therapy: a case report.. J Med Case Rep, 19(1), 622. https://doi.org/10.1186/s13256-025-05660-x

28/11/2025 Lire →

Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study.

INTRODUCTION: The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an intermediate stage, and current treatment options are associated with unfavourable overall prognosis. Thi…

Thérapies de Conversion

Zhou, Y., Wang, H., Wu, J., Shen, J., Ma, J., Li, Q., Chen, W., Lu, W., Feng, X., Yan, M., Wen, T., & Zhang, X. (2025). Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study.. Liver Cancer. https://doi.org/10.1159/000549684

24/11/2025 Lire →

Response evaluation to systemic therapy in HCC: Current challenges and future perspectives.

In oncology, the radiological assessment of treatment response is crucial for predicting therapeutic efficacy in terms of survival, both in clinical trials and daily practice. However, this fundamenta…

Thérapies de Conversion

Matute-González, M., Ronot, M., Chernyak, V., Sangro, B., & Rimola, J. (2025). Response evaluation to systemic therapy in HCC: Current challenges and future perspectives.. Hepatology. https://doi.org/10.1097/HEP.0000000000001621

19/11/2025 Lire →

Toripalimab combined with FLOT chemotherapy as conversion therapy for gastric cancer with peritoneal metastasis: a single-arm, open-label, phase II trial.

BACKGROUND: The combination of PD-1/PD-L1 monoclonal antibodies and chemotherapy has established a new standard of care for the first-line treatment of patients with unresectable locally advanced or m…

Thérapies de Conversion

Zhang, Z., Lin, Z., Xu, Y., Luo, L., Zeng, H., Xiong, W., Chen, Y., Peng, Y., Yang, T., Zheng, Y., Li, J., Huang, H., & Wang, W. (2025). Toripalimab combined with FLOT chemotherapy as conversion therapy for gastric cancer with peritoneal metastasis: a single-arm, open-label, phase II trial.. BMC Cancer, 25(1), 1733. https://doi.org/10.1186/s12885-025-15166-w

08/11/2025 Lire →

Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.

OBJECTIVE/BACKGROUND: The RNPLS-01 trial aimed to evaluate the efficacy and safety of ramucirumab (a VEGFR2 antagonist) combined with nab-paclitaxel, lobaplatin, and S-1 (RNPLS group) versus nab-pacli…

Thérapies de Conversion

Wang, J., Feng, F., Du, K., Yang, X., Liu, S., Xu, C., Li, M., Tan, Z., Li, X., Wang, S., Yang, X., Li, S., Yu, P., Wei, J., Xu, G., Hong, L., Zheng, J., & Yang, J. (2025). Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.. Int J Surg, 111(11), 8060-8069. https://doi.org/10.1097/JS9.0000000000002893

01/11/2025 Lire →

[Efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma].

To evaluate the efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma. This retrospecti…

Thérapies de Conversion

Lyu, K. L., Wang, M. B., Gai, C. Y., Zhang, F., Zhu, Y. G., Liu, Y., Li, J. C., Ding, W. L., Xu, S., Li, Z. H., Sun, B. K., Gao, W. D., & Tian, Z. Z. (2025). [Efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma].. Zhonghua Wai Ke Za Zhi, 63(11), 1023-1030. https://doi.org/10.3760/cma.j.cn112139-20250624-00318

01/11/2025 Lire →